274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Sarah Cohen , Jacob Waldman , Andrew Dunn , Thao Nguyen , Jonathan Terrett , Brigid Mcewan , Meghna Kuppuraju , Mohammed Ghonime , Robert Chain , Zinkal Padalia , Demetrios Kalaitzidis , Elizabeth Koch , Lauren Zakas , Nivedita Jaishankar , Davis Settipane , Paul Tetteh , Mary-Lee Dequeant , Sushant Karnik , Chandirasegaran Massilamany , Henia Dar , Melanie Allen , Laura Serwer , Melanie Butler-Gauthier , Parin Sripakdeevong , Shashwat Nagar , Yin Tang , Nicole Flanagan , Elaine Huang , Shashwant Phuyal , Erisa Sula , Maria Lei Zhang , Cristian Loaiza , Erin Thorstensen , Keith Steiger , Katie Schum , Kayla Urbaez , Anna Ma , Annie Yang Weaver , Christopher Finch , PK Morrow , Mark Benton Journal for ImmunoTherapy of Cancer（2023）
关键词
cart cell therapy, tgfbr2, ctx112, genes, crispr-edited
AI 理解论文
溯源树
样例
